home / stock / apvo / apvo short
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 373,411 |
Total Actual Volume | 2,277,515 |
Short Trends | |
---|---|
Cover Days | 4 |
Short Days | 10 |
No Change Days | 6 |
Averages | |
---|---|
Average Short Volume | 18,671 |
Average Short Percentage | 50.60% |
Is there a APVO Short Squeeze or Breakout about to happen?
See the APVO Short Analysis for free Sign up or Login
Powered by Squeeze Report
Stock Date | Open Price | Close Price | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
2022-06-23 | 3.96 | 4.01 | 4.19 | 3.795 | 66,362 | 14,281 | 39.4895 |
2022-06-22 | 3.56 | 3.91 | 3.94 | 3.5391 | 36,413 | 3,767 | 27.8192 |
2022-06-21 | 3.57 | 3.7 | 3.8 | 3.5178 | 68,273 | 21,061 | 52.8176 |
2022-06-16 | 3.3 | 3.26 | 3.4136 | 3.14 | 44,710 | 10,451 | 50.1825 |
2022-06-15 | 3.34 | 3.3 | 3.47 | 3.03 | 184,452 | 30,024 | 39.0663 |
2022-06-14 | 3.47 | 3.32 | 3.49 | 3.28 | 100,065 | 16,769 | 49.1111 |
2022-06-13 | 3.96 | 3.53 | 3.96 | 3.4501 | 142,207 | 26,654 | 43.6679 |
2022-06-09 | 6.1 | 4.86 | 6.5199 | 4.7 | 1,354,104 | 190,922 | 49.9350 |
2022-06-08 | 5.57 | 5.68 | 5.68 | 5.14 | 19,946 | 4,350 | 52.2711 |
2022-06-06 | 4.83 | 5.15 | 5.1699 | 4.83 | 16,689 | 802 | 26.2951 |
2022-06-03 | 4.72 | 4.99 | 4.99 | 4.66 | 15,981 | 1,603 | 47.7083 |
2022-06-02 | 4.7399 | 4.72 | 4.7399 | 4.5 | 6,161 | 1,259 | 64.3003 |
2022-06-01 | 4.59 | 4.52 | 4.675 | 4.5124 | 9,968 | 3,842 | 83.3948 |
2022-05-31 | 4.695 | 4.58 | 4.84 | 4.58 | 10,405 | 1,404 | 22.0443 |
2022-05-27 | 4.67 | 4.88 | 4.97 | 4.55 | 38,808 | 7,034 | 54.0952 |
2022-05-26 | 4.75 | 4.7 | 5.28 | 4.59 | 79,248 | 14,310 | 29.4226 |
2022-05-25 | 4.75 | 4.84 | 4.84 | 4.6684 | 11,145 | 990 | 78.4469 |
2022-05-24 | 4.7 | 4.75 | 4.81 | 4.48 | 18,352 | 6,654 | 60.8560 |
2022-05-23 | 4.56 | 4.83 | 4.95 | 4.4703 | 45,304 | 13,507 | 50.5653 |
2022-05-19 | 4.67 | 4.83 | 4.87 | 4.63 | 8,922 | 3,727 | 90.5051 |
Aptevo Therapeutics Inc. Company Name:
APVO Stock Symbol:
NASDAQ Market:
Aptevo Therapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable an...
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologie...
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...